Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant
Mediastinal gray zone lymphoma (MGZL) is a rare, predominantly adult hematologic malignancy with pathologic features of both primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkins lymphoma (cHL) [ 1 ].Overlapping pathologic features make MGZL diagnostically challenging.Additionally, treatment regimens are poorly defined given rarity and aggressive clinical course.Adult MGZL is usually managed with PMBLstyle chemotherapy, yet with significantly worse outcomes than PMBL and cHL [ 2,3 ].For relapsed disease, definitive therapy is autologous hematopoietic stem cell transplant (aHSCT) [ 4 ].
Authors
- Susan R. Rheingold (ORCID: https://orcid.org/0000-0001-8025-6767)
- Julia Wang (ORCID: https://orcid.org/0000-0002-6984-8283)
- Matthew Schuelke (ORCID: https://orcid.org/0000-0002-8399-1537)
- Haley Newman
- M. Takeda
- Evelyn Kurpiewski
- Anne Reilly
- Gerald Wertheim
- Daniel J. Zheng
- Kaitlin Devine
Institutions
- Children's Hospital of Philadelphia (US)
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-08-27
- DOI
- https://doi.org/10.1002/1545-5017.70622
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- St. Baldrick's Foundation
- National Institutes of Health
- National Cancer Institute